DSM-Firmenich - Public Comps and Valuation Multiples

DSM-Firmenich Overview

About DSM-Firmenich

DSM-Firmenich is a global science-based company formed in 2023 through the merger of DSM, a Dutch nutrition, health, and sustainable living player, and Switzerland-based Firmenich, the third-largest player in the flavor and fragrance market. The company serves a wide range of end-consumer markets providing nutrition solutions ranging from animal feed to medical and early-life nutrition, fragrances for personal-, home-, and laundry-care brands, prestige perfumes, and other ingredients for food and beverage, home, and personal care. DSM-Firmenich has nearly 30,000 employees, with more than 2,000 scientists and engineers spread across 15 research and development facilities.

Founded

2022

HQ

Employees

28.2K+

Website

dsm-firmenich.com

Sectors

Chemicals

Financials

LTM Revenue $15.0B

LTM EBITDA $2.7B

EV

$26.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

DSM-Firmenich Financials

As of August 2025, DSM-Firmenich reported last 12-month revenue of $15.0B and EBITDA of $2.7B.

In the same period, DSM-Firmenich generated $5.1B in LTM gross profit and $853M in net income.

See DSM-Firmenich valuation multiples based on analyst estimates

DSM-Firmenich P&L

In the most recent fiscal year, DSM-Firmenich reported revenue of $15.0B and EBITDA of $2.1B.

DSM-Firmenich expects next 12-month revenue of XXX and NTM EBITDA of XXX

See DSM-Firmenich valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$15.0B	XXX	$15.0B	XXX	XXX	XXX
Gross Profit	$5.1B	XXX	$5.0B	XXX	XXX	XXX
Gross Margin	34%	XXX	33%	XXX	XXX	XXX
EBITDA	$2.7B	XXX	$2.1B	XXX	XXX	XXX
EBITDA Margin	18%	XXX	14%	XXX	XXX	XXX
EBIT	$1.5B	XXX	$632M	XXX	XXX	XXX
EBIT Margin	10%	XXX	4%	XXX	XXX	XXX
Net Profit	$853M	XXX	$293M	XXX	XXX	XXX
Net Margin	6%	XXX	2%	XXX	XXX	XXX
Net Debt	XXX	XXX	$2.4B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for DSM-Firmenich including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $15.0B. EBITDA for the last twelve months was $2.7B. In the most recent fiscal year, DSM-Firmenich achieved $15.0B in revenue and $2.1B in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$15.0B	Analyst estimates available to subscribers	$15.0B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$5.1B	Analyst estimates available to subscribers	$5.0B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	33.7% gross margin	Analyst estimates available to subscribers	33.2% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$2.7B	Analyst estimates available to subscribers	$2.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	17.7% EBITDA margin	Analyst estimates available to subscribers	14.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$1.5B	Analyst estimates available to subscribers	$632M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	9.7% EBIT margin	Analyst estimates available to subscribers	4.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$853M	Analyst estimates available to subscribers	$293M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	5.7% net profit margin	Analyst estimates available to subscribers	2.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$2.4B	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for DSM-Firmenich

This financial data table provides comprehensive performance metrics for DSM-Firmenich, a company based in Netherlands. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

DSM-Firmenich generated $15.0B in revenue over the last twelve months.
The company achieved $2.7B in EBITDA over the last twelve months.
Gross profit for the last twelve months was $5.1B.
Net income over the last twelve months reached $853M.

Fiscal Year Performance

In the most recent fiscal year, DSM-Firmenich reported $15.0B in total revenue.
Fiscal year EBITDA was $2.1B.
The company maintained a gross profit margin of 33.2% in the most recent fiscal year.
EBITDA margin for the fiscal year was 14.0%.
Net profit margin reached 2.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for DSM-Firmenich. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

DSM-Firmenich Stock Performance

DSM-Firmenich has current market cap of EUR 20.1B (or $23.6B), and EV of EUR 22.7B (or $26.6B).

Market Cap Evolution

DSM-Firmenich Stock Data

As of September 18, 2025, DSM-Firmenich's stock price is EUR 78 (or $92).

See DSM-Firmenich trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$26.6B	$23.6B	XXX	XXX	XXX	XXX	$4.30

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

DSM-Firmenich Valuation Multiples

DSM-Firmenich's trades at 1.8x EV/Revenue multiple, and 12.7x EV/EBITDA.

See valuation multiples for DSM-Firmenich and 15K+ public comps

DSM-Firmenich Financial Valuation Multiples

As of September 18, 2025, DSM-Firmenich has market cap of $23.6B and EV of $26.6B.

Equity research analysts estimate DSM-Firmenich's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

DSM-Firmenich has a P/E ratio of 27.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$23.6B	XXX	$23.6B	XXX	XXX	XXX
EV (current)	$26.6B	XXX	$26.6B	XXX	XXX	XXX
EV/Revenue	1.8x	XXX	1.8x	XXX	XXX	XXX
EV/EBITDA	10.0x	XXX	12.7x	XXX	XXX	XXX
EV/EBIT	18.2x	XXX	42.1x	XXX	XXX	XXX
EV/Gross Profit	5.2x	XXX	n/a	XXX	XXX	XXX
P/E	27.6x	XXX	80.4x	XXX	XXX	XXX
EV/FCF	24.0x	XXX	22.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get DSM-Firmenich Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

DSM-Firmenich Margins & Growth Rates

DSM-Firmenich's last 12 month revenue growth is 1%

DSM-Firmenich's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

DSM-Firmenich's rule of 40 is 8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

DSM-Firmenich's rule of X is 19% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for DSM-Firmenich and other 15K+ public comps

DSM-Firmenich Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	1%	XXX	0%	XXX	XXX	XXX
EBITDA Margin	18%	XXX	14%	XXX	XXX	XXX
EBITDA Growth	3%	XXX	68%	XXX	XXX	XXX
Rule of 40	8%	XXX	15%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	19%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	14%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	7%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	29%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial